A team led by Takahashi Jun at Kyoto University in Japan has used induced pluripotent stem cells (iPS cells) to differentiate into neurons and implanted them into the brains of Parkinson's disease patients. So far, seven patients have received the treatment. The transplanted neurons are capable of secreting dopamine, and preliminary observations indicate potential for improving motor function. This research is one of the core projects of the Japanese government's 'Healthy Longevity Society' strategy, aiming to address the challenges of an aging population through regenerative medicine. Several Japanese companies, such as Sumitomo Pharma, have established iPS cell mass production facilities, paving the way for future commercialization. Although the efficacy still needs further verification, this technology offers a new direction for the treatment of neurodegenerative diseases.